147 related articles for article (PubMed ID: 23675804)
1. De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression.
Igawa T; Sato Y; Takata K; Iwaki N; Tanaka T; Asano N; Maeda Y; Orita Y; Nakamura N; Nakamura S; Yoshino T
Diagn Pathol; 2013 May; 8():81. PubMed ID: 23675804
[TBL] [Abstract][Full Text] [Related]
2. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.
Metcalf RA; Zhao S; Anderson MW; Lu ZS; Galperin I; Marinelli RJ; Cherry AM; Lossos IS; Natkunam Y
Mod Pathol; 2010 Mar; 23(3):420-33. PubMed ID: 20062012
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
4. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
Chuang WY; Chang ST; Yuan CT; Chang GJ; Chang H; Yeh CJ; Ueng SH; Kao HW; Wang TH; Wan YL; Shih LY; Chuang SS; Hsueh C
Am J Surg Pathol; 2020 Feb; 44(2):232-240. PubMed ID: 31688139
[TBL] [Abstract][Full Text] [Related]
5. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.
Cao X; Fan L; Fang C; Zhu DX; Dong HJ; Wang DM; Wang YH; Xu W; Li JY
Med Oncol; 2012 Jun; 29(2):1190-6. PubMed ID: 21479697
[TBL] [Abstract][Full Text] [Related]
6. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
8. Large cell variants of CD5+, CD23- B-cell lymphoma/leukemia.
Dunphy CH; Perkins SL
Arch Pathol Lab Med; 2001 Apr; 125(4):513-8. PubMed ID: 11260626
[TBL] [Abstract][Full Text] [Related]
9. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
[TBL] [Abstract][Full Text] [Related]
10. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus.
Ehinger M; Linderoth J; Christensson B; Sander B; Cavallin-Ståhl E
Am J Clin Pathol; 2008 Apr; 129(4):630-8. PubMed ID: 18343791
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity.
Yatabe Y; Nakamura S; Seto M; Kuroda H; Kagami Y; Suzuki R; Ogura M; Kojima M; Koshikawa T; Ueda R; Suchi T
Am J Surg Pathol; 1996 Sep; 20(9):1110-22. PubMed ID: 8764748
[TBL] [Abstract][Full Text] [Related]
12. Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Salek D; Jarkovsky J; Smarda J; Smardova J
Oncol Rep; 2016 May; 35(5):2673-80. PubMed ID: 26985765
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclin D2 and D3 in lymphoid lesions.
Teramoto N; Pokrovskaja K; Szekely L; Polack A; Yoshino T; Akagi T; Klein G
Int J Cancer; 1999 May; 81(4):543-50. PubMed ID: 10225442
[TBL] [Abstract][Full Text] [Related]
14. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma.
Kroft SH; Howard MS; Picker LJ; Ansari MQ; Aquino DB; McKenna RW
Am J Clin Pathol; 2000 Oct; 114(4):523-33. PubMed ID: 11026098
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
16. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.
Mircean C; Tabus I; Kobayashi T; Yamaguchi M; Shiku H; Shmulevich I; Zhang W
Int J Oncol; 2004 Mar; 24(3):497-504. PubMed ID: 14767533
[TBL] [Abstract][Full Text] [Related]
17. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
18. De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course.
Ramachandran P; Sahni S; Wang JC
J Investig Med High Impact Case Rep; 2019; 7():2324709619893546. PubMed ID: 31814435
[TBL] [Abstract][Full Text] [Related]
19. CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma.
Yamamoto N; Maeshima AM; Taniguchi H; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Hum Pathol; 2021 May; 111():84-91. PubMed ID: 33727166
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]